<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59413">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332538</url>
  </required_header>
  <id_info>
    <org_study_id>Mans-2014-05</org_study_id>
    <nct_id>NCT02332538</nct_id>
  </id_info>
  <brief_title>HoLEP vs. Greenlight 532nm-laser PVEP vs. Bipolar TURP in Management of Moderate/ Large BPH</brief_title>
  <official_title>Randomized Trial Comparing Holmium Laser Enucleation of the Prostate vs. Greenlight 532nm-laser Vapo-Enucleation of the Prostate vs. Bipolar Transurethral Resection of the Prostate in Management of Moderate/Large Benign Prostate Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most guidelines are not strict for recommending single treatment approach for Moderate to
      large prostate.

      In this study the investigators planned to test the Greenlight (532-nm) laser Photoselective
      Vapo-Enucleation of the Prostate (PVEP) using (XPS) 180W system compared to bipolar
      transurethral resection of the prostate (TURis) and Holmium Laser Enucleation of the
      Prostate (HOLEP) in reduction of lower urinary tract symptoms (LUTS) secondary to BPH in a
      prospective randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With a growing body of knowledge on the promising advancements and recent clinical data of
      the third generations of the Greenlight XPS, it seems to be a real contender in the world of
      MIS. Contenders of Greenlight laser technology includes bipolar as well as Holmium laser
      technology.

      In this study the investigators planned to test the Greenlight (532-nm) laser Photoselective
      Vapo-Enucleation of the Prostate (PVEP) using (XPS) 180W system compared to bipolar
      transurethral resection of the prostate (TURis) and Holmium Laser Enucleation of the
      Prostate (HOLEP) in reduction of LUTS secondary to BPH in a prospective randomized trial.

      Furthermore, all peri-operative parameters, urinary flow parameters, prostate size changes
      and complications associated with the procedures were compared. The prostate size
      limitations will be assessed in relation to the outcome measures.

      Moderate to large size prostate (80-120 ml TRUS estimated volume) will be randomized to PVEP
      vs. Bipolar TURP vs. HoLEP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>1 YEAR</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-Operation (need for reintervention for infravesical obstruction following primary surgery)</measure>
    <time_frame>1 year</time_frame>
    <description>need for reintervention for infravesical obstruction following primary surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Flow rate (ml/sec)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Greenlight (532nm-laser) PVEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>532nm-laser photoselective vapo-enucleation of the prostate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Holmium laser enucleation of prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Holmium-Yag laser enucleation of the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar TURP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bipolar transurethral resection of the prostate in saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>532nm-laser photoselective vapo-enucleation of the prostate)</intervention_name>
    <description>using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)</description>
    <arm_group_label>Greenlight (532nm-laser) PVEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Holmium laser enucleation of prostate</intervention_name>
    <description>Holmium-Yag laser enucleation of the prsotate</description>
    <arm_group_label>Holmium laser enucleation of prostate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bipolar TURP</intervention_name>
    <description>Bipolar transurethral resection of the prostate in saline</description>
    <arm_group_label>Bipolar TURP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients' age ≥50 years

          2. LUTS secondary to BOO due to BPH who failed medical treatment

          3. International prostate symptom scores 8 (IPSS) &gt;15 and bother score 8 (QOL) ≥ 3
             (according to IPSS question 8)

          4. Peak urinary flow rate (Qmax) &lt;15 ml/sec with at least 125 ml voided volume or
             Patients with acute urine retention secondary to BPH who failed trial of voiding on
             medical treatment.

          5. ASA (American society of anaesthesiologists) score ≤3.

          6. TRUS prostate size (80-120)

        Exclusion Criteria:

          1. Patient with neurological disorder which might affect bladder function as
             cerebrovascular stroke, Parkinson disease

          2. Active urinary tract infection,

          3. Presence of active bladder cancer (within the last 2 years)

          4. Known prostate cancer patients will be excluded preoperatively on the basis of
             digital rectal examination, prostate specific antigen level, and TRUS imaging
             followed by prostate biopsies if necessary.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Elshal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura Urology and Nephrology center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmed m elshal, MD</last_name>
    <phone>+201001855490</phone>
    <email>ELSHALAM@HOTMAIL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmoud N Laymoun, MD</last_name>
    <phone>+20502262222</phone>
    <phone_ext>1428</phone_ext>
    <email>dr_mahmoudlaymon@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Elshal, MD</last_name>
      <phone>00201001855490</phone>
      <email>elshalam@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M Elshal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed M Elasmy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahmoud N laymoun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 7, 2016</lastchanged_date>
  <firstreceived_date>December 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Elshal</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>LASER</keyword>
  <keyword>PROSTATE</keyword>
  <keyword>BIPOLAR</keyword>
  <keyword>HYPERPLASIA</keyword>
  <keyword>VAPORIZATION</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
